百济神州（BGNE.US）2022年ESG报告（中译版）（71页）.pdf

1、Change Is The Cure2022 Environmental,Social,and Governance ReportA Letter from the CEO 3About BeiGene .4About This Report .4 Our Approach 5ESG Strategy and Goals .6Our Progress .7Our Material Topics .9Advancing Global Health 10A Differentiated Approach .11Pursuing Broad Access to Our Medicines .15Pa

2、tient Safety and Product Quality Systems .20Transparency in Interactions with Stakeholders .24Empowering Our People 25Colleague Engagement and Well-Being.26Development Planning.29Health and Safety .30A Culture of Belonging .31Innovating Sustainably 35Our Climate Strategy .36Our Environmental Perform

3、ance.38Supporting Communities 41Patient Engagement and Advocacy.42Employee Volunteerism and Charitable Giving.45Operating Responsibly 46Corporate Governance .47Responsible Procurement.49Global Reporting Initiative/Hong Kong Exchange Limited Index 50Table of ContentsContentsOverviewAdvancing Global H

4、ealthEmpowering Our PeopleInnovating SustainablySupportingCommunitiesOperatingResponsiblyGlobal Reporting Initiative/Hong Kong Exchange Limited Index2:2022 BEIGENE ESG REPORTA Letter from the CEOChange propels new ways of thinking,operating,and innovating.Change Is the Cure,BeiGenes ESG strategy,fra

5、mes our approach for helping change the world for the better.It begins with our commitment to advancing global health by making innovative medicines more accessible to more people around the world.In 2022,our oncology research team,one of the largest such teams in the world,brought three new molecul

6、es to the clinic,for a total of 16 since our founding in 2010.Currently,we have more than 60 preclinical programs,with the majority having first-in-class or best-in-class potential.Starting in 2024,we anticipate 10 or more new molecules entering the clinic each year.Since 2013,we have conducted more